Chemotactic Properties of Angiopoietin-1 and -2, Ligands for the Endothelial-specific Receptor Tyrosine Kinase Tie2*

Bernhard Witzenbichler, Peter C. MaisonpierreDagger , Pamela JonesDagger , George D. YancopoulosDagger , and Jeffrey M. Isner§

From the Department of Cardiovascular Research, St. Elizabeth's Medical Center of Boston, Tufts University School of Medicine, Boston, MA 02135 and Dagger  Regeneron Pharmaceuticals, Inc., Tarrytown, New York 10591

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Angiopoietin-1 and its putative natural antagonist, angiopoietin-2, were recently isolated, and the critical role of angiopoietin-1 in embryogenic angiogenesis was demonstrated by targeted gene disruption. Specific biological effects of angiopoietin-1, however, have yet to be defined. In this study we demonstrate that angiopoietin-1, but not angiopoietin-2, is chemotactic for endothelial cells. In contrast, angiopoietin-1 as well as angiopoietin-2 exhibit no proliferative effect on endothelial cells. Excess soluble Tie2, but not Tie1 receptor, abolish the chemotactic response of endothelial cells toward angiopoietin-1. Angiopoietin-2 dose-dependently blocks directed migration toward angiopoietin-1, consistent with the role of angiopoietin-2 as a naturally occurring inhibitor of angiopoietin-1. Fibroblasts stably transfected with Tie2 receptor exhibit chemotactic responses for both angiopoietin-1 and angiopoietin-2. Fibroblasts stably expressing a transfected chimeric receptor consisting of the ectodomain of TrkC fused to the cytoplasmic domain of Tie2 also exhibit a chemotactic response to neurotrophin 3 (NT-3), a specific ligand for TrkC. Endothelial cells are shown to express angiopoietin-2 mRNA and protein, indicating the potential for autocrine activation of angiopoietin/Tie2. Finally, the demonstration that Tie2 as well as angiopoietin-1 are expressed in normal human arteries and veins suggests that the role of angiopoietin/Tie2 may extend beyond embryonic angiogenesis to maintaining integrity of the adult vasculature.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

The receptor tyrosine kinase family of cell surface proteins is known to play key roles in transducing intercellular signals to the cytoplasm (1). A large diversity of receptor tyrosine kinases and receptor tyrosine kinase expression patterns, which are temporally modified during development and under pathologic conditions, determines cell fate and allows tissue-specific cell responses. Ligand binding to the large extracellular domain of receptor tyrosine kinases leads to receptor dimerization and autophosphorylation of tyrosine residues on the intracellular domain of the receptor (2). A variety of Src homology 2 domain-containing proteins, which are recruited to these phosphorylation sites, have been identified (3). These proteins are regarded as initiators of different signal cascades that finally lead to specific cellular responses including proliferation, migration, differentiation, and morphologic organization in the context of surrounding tissues (4).

On the basis of sequence similarity and structural characteristics, it is possible to classify receptor tyrosine kinases into subfamilies (1). Two receptor tyrosine kinase subfamilies are characterized by their largely endothelium-specific expression. One of them consists of the three known vascular endothelial growth factor (VEGF)1 receptors Flt-1/VEGF-R1, Flk-1/KDR/VEGF-R2, and Flt-4/VEGF-R3 (5, 6). The critical role of these receptors in promoting vasculogenesis and angiogenesis during normal embryogenesis was demonstrated using mutant mice with targeted disruption of the flt-1 (7) or flk-1 gene (8). Moreover, expression of these receptors in the endothelial layer of adult blood vessels (9) is thought to mediate VEGF-induced post-natal angiogenesis in pathologic (10-12) or therapeutic settings (13, 14) but is also believed to be important in maintaining vessel integrity (15).

The Tie (tyrosine kinase with immunoglobulin (Ig) and epidermal growth factor (EGF) homology domains) receptor family comprises a second endothelial-specific subfamily of receptor tyrosine kinases termed Tie1 (16-19) and Tie2/Tek (16, 20, 21). Similar to the VEGF receptors, both receptors have been shown to be critically involved in the formation of embryonic vasculature. Tie1 null mice (22, 23) as well as mice deficient in Tie2 (24) display a lethal phenotype caused by severe defects in embryonic vasculature. Moreover, an activating mutation in the Tie2 receptor was shown to cause inherited venous malformations in humans (25); these malformed vessels exhibited a disproportionately large number of endothelial cells (ECs) versus smooth muscle cells (SMCs), underlining the importance of an intact Tie2 receptor system for EC-SMC communication in vascular morphogenesis.

Although the ligands of the three VEGF receptors, their binding patterns, and their functions are relatively well characterized (5, 6, 26), the ligand for the Tie2 receptor, named angiopoietin-1 (Ang1), was only recently isolated (27), whereas the ligand(s) for the Tie1 receptors are still unknown. Targeted disruption of the Ang1 gene in mice resulted in an embryonic lethal phenotype by day 12.5 with generalized defects in vascular structure reminiscent of those previously observed in mice lacking Tie2 (28). Ang1 protein phosphorylated Tie2 receptor in a variety of ECs but did not induce EC growth or tube formation (27). In fact, no in vitro assay to date has demonstrated any biological function of Ang1 for ECs. Analysis of Ang1 mRNA expression in adult tissues revealed abundant expression in highly vascularized tissues such as skeletal muscle, prostate, ovary, uterus, and placenta (29), suggesting a role of Ang1 not only in embryonic angiogenesis but also in the adult vasculature. Given the paucity of in vitro data, however, the physiologic contribution of Ang1 to these processes remains enigmatic. The temporal appearance of embryonic Ang1 expression suggests that the Ang1/Tie2 system is not involved in the initial vasculogenic phase of vascular development (as shown for the VEGF system) but rather participates in angiogenic outgrowth (sprouts), vessel remodeling, and vascular maturation (22, 24, 8). The recent discovery of a natural antagonist for Tie2, named angiopoietin-2 (Ang2), that binds to Tie2 but does not transduce the receptor has added a further level of complexity to regulation by the Ang/Tie2 system (29).

Findings described in the current study are the first to our knowledge to demonstrate an in vitro effect of Ang1 on ECs. We show that Ang1, but not Ang2, is a potent and specific chemotactic protein when administered to ECs. Neither Ang1 nor Ang2 was found to be mitogenic for ECs. In contrast to other angiogenic cytokines (30, 31), both Ang1 and Ang2 were also devoid of anti- or pro-apoptotic effects. The chemotactic response of ECs toward Ang1 could be abolished by excess soluble Tie2, but not Tie1 receptor, as well as by increasing amounts of Ang2. In contrast to findings shown for Ang2 and ECs, fibroblasts stably transfected with Tie2 receptor exhibited strong chemotactic responses for Ang2 as well as Ang 1, consistent with previous observations that Ang2 can activate Tie2 receptors in non-ECs. Finally, the demonstration of Tie2 as well as Ang1 expression in adult normal arterial and venous specimens suggests a potential role for Tie2/Ang1 in the maintenance of vascular integrity.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Cell Culture and Media-- Human umbilical vein endothelial cells (HUVECs) were isolated from umbilical cord vein by collagenase treatment as described previously (32) and grown in medium 199 (M199) (Life Technologies, Inc.) supplemented with 20% fetal bovine serum (FBS) (Life Technologies), 100 µg/ml EC growth supplement, and 50 units/ml heparin (Sigma). HUVECs were used between passages 3 and 5. Human microvascular (HM) ECs of dermal origin were purchased from Clonetics, grown in EBM medium containing human epidermal growth factor (10 ng/ml), hydrocortisone (10 ng/ml), 5% FBS, and 0.4% bovine brain extract (Clonetics). Human microvascular endothelial cells were used between passages 4 and 6. Rat vascular smooth muscle cells were extracted from rats as described previously (33) and cultured in Dulbecco's modified Eagle's medium supplemented with 10% FBS. Human vascular smooth muscle cells were derived by explant outgrowth from unused portions of saphenous veins obtained at coronary bypass surgery as described previously (34) and cultured in Dulbecco's modified Eagle's medium supplemented with 15% FBS. NIH 3T3 fibroblasts were purchased from the American Type Culture Collection and maintained in 10% FBS. Stable transfections of fibroblasts with an expression plasmid encoding full-length Tie2 receptor cDNA, a chimeric receptor consisting of the ectodomain of TrkC fused to the cytoplasmic domain of Tie2 or with empty vector (mock), were produced as before (29).

Recombinant Proteins-- Ang1* and Ang2 recombinant protein were produced using baculovirus vectors and purified using protein A-Sepharose as described previously (27). (In the case of Ang1, the protein used for these in vitro studies was modified from the original and has been designated Ang1* (29)). The purity of proteins was greater than 95% as judged by reducing and nonreducing silver-stained SDS-polyacrylamide gel electrophoresis. Soluble Tie1 receptor-Fc (rTie1-Fc) and Tie2 receptor-Fc (rTie2-Fc) fusion proteins were constructed, produced, and purified as described recently (27). Heterodimeric recombinant human VEGF165 protein purified from Escherichia coli was a generous gift of Drs. N. Ferrara, B. Keyt, and S. Bunting at Genentech Inc.

Cell Proliferation Assay-- Cell proliferation was assayed using the colorimetric MTS (3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium) assay with the electron coupling reagent phenazine methosulfate (CellTiter 96 AQ, Promega). This assay was previously validated and demonstrated to positively correlate with cell number (35). Cells were seeded in a fibronectin-coated 96-well plate (5 × 103 cells/well) in 0.1 ml of serum-supplemented medium and allowed to attach overnight. Factors in 5% FBS were added to the wells for 48 h as indicated. MTS/phenazine methosulfate mixture (20 µl) was added to each well and allowed to incubate for 1 h at 37 °C before measuring absorbance at 490 nm in an enzyme-linked immunosorbent assay plate reader. Background absorbance from control wells was subtracted, and seven wells were performed in parallel for each condition.

Measurement of DNA Synthesis-- EC DNA synthesis was evaluated by [3H]thymidine incorporation assay. A total of 2 × 104 cells/well in M199 containing 5% FBS were seeded in 24-well plates, coated with 1.5% gelatin, and allowed to attach overnight. Specific conditions (see below) were employed for 48 h before the addition of 2 µl/ml [3H]thymidine (Amersham Pharmacia Biotech). After 4 h, cells were washed with phosphate-buffered saline, precipitated with 10% trichloroacetic acid, lysed in 0.25 N NaOH, and then transferred into glass vials filled with scintillation liquid. Radioactivity was measured in a Beckman counter and expressed as counts/min (cpm). The addition of phorbol 12-myristate 13-acetate (Sigma) was used as a positive control to induce [3H]thymidine incorporation. Each sample was done in triplicate.

Flow Cytometry-- To quantify apoptosis, floating and adhesive cells were collected after treatment as indicated using trypsin and washed and resuspended in ice-cold 70% ethanol. For cell cycle analysis, only adhesive cells were considered. After fixing overnight at 4 °C, cells were stained with 50 µg/ml propidium iodide (Boehringer Mannheim) in phosphate-buffered saline, pH 7.4, containing 0.1% (w/v) Triton X-100 (Sigma), 0.5 mM EDTA, and 50 µg/ml RNase A (50 units/l, Sigma) at 4 °C for at least 1 h. DNA content was analyzed from 1 × 105 events/group using a fluorescent-activated cell sorter Scan cytometer (Becton Dickinson) with Lysys II software. Cells with less fluorescence intensity than the G1 peak were regarded as apoptotic and expressed as a percentage of total number of cells analyzed. Cell cycle statistics were calculated using CellFit Cell-Cycle software (Becton Dickinson).

Cell Migration Assay-- EC migration assays were performed using a 48-well microchemotaxis chamber (Neuroprobe) (36). Polyvinylpyrrolidone-free polycarbonate filters with a pore size of 8 µm (Nuclepore) were coated with 50 µg/ml fibronectin and 0.1% gelatin in phosphate-buffered saline for at least 6 h at room temperature and dried under sterile air. Test substances were diluted to appropriate concentrations in M199 supplemented with 1% FBS, and 25 µl of the final dilution was placed in the lower chamber of a modified Boyden chamber. Confluent cell cultures were washed and trypsinized for the minimum time required to achieve cell detachment. After placing the filter between lower and upper chambers, 2.5 × 105 cells suspended in 50 µl of M199 containing 1% FBS were seeded in the upper compartment. The apparatus was then incubated for 5 h at 37 °C in a humidified chamber with 5% CO2 to allow cell migration. After the incubation period, the filter was removed, and the upper side of the filter containing the nonmigrated cells was scraped with a rubber policeman. The filters were fixed with methanol and stained with Giemsa solution (Diff-Quick, Baxter). Migration was quantified by counting cells in three random high power fields (100×) in each well. All groups were studied in quadruplicate.

Analysis of Angiopoietin-1, Angiopoietin-2, and Tie2 Receptor mRNA in Cultured Cells and Human Vessel Specimens-- Unused segments of human internal mammary artery, radial artery, and saphenous vein were obtained during bypass surgery, as described previously (9); these specimens were retrieved from the operating room at the time of excision and were promptly processed to avoid degradation of RNA. Care was taken to remove these segments in a nontraumatic manner, including limiting manipulation of the specimens to the ends of the vascular segments. Total RNA from these specimen or from cell cultures as indicated was immediately isolated by phenol/chloroform extraction (37), and RNA concentration was calculated from absorbance at 260 nm.

Reverse transcription (RT) (38) was performed by heating a 10 µl reaction mixture containing 1 µg of total RNA and 20 µg/ml oligodeoxythymidine (Life Technologies, Inc.) at 70 °C for 10 min. After cooling, 60 units of human placenta ribonuclease inhibitor (Promega) and 200 units of Moloney's murine leukemia virus RNase H reverse transcriptase (Life Technologies, Inc.) were added in a final 20-µl reaction mixture containing 1 mmol/l each dNTP (Amersham), 10 mmol/l dithiothreitol, 25 mmol/l Tris-HCl, pH 8.3, 75 mmol/l KCl, and 3mmol/l MgCl2, incubated for 1 h at 42 °C, heated 5 min at 95 °C, and diluted to 50 µl with double-distilled water. For the polymerase chain reaction (PCR) (39), a 50-µl reaction containing 5 µl of cDNA-RNA hybrids, 200 µmol/l dNTP (Amersham), 20 mmol/l Tris-HCl, pH 8.55, 2.5 mmol/l MgCl2, 16 mmol/l (NH4)2SO4, 150 µg/ml BSA, 1 µmol/l each oligonucleotide primer, and 1.25 units of Taq polymerase (Perkin-Elmer) was subjected to the following temperature cycles: 30 s of denaturing at 95 °C, 5 s of annealing at 56 °C, and 1 min of extension at 72 °C. At the end of the last cycle, a prolonged extension step was carried out for 10 min. PCR products were analyzed by electrophoreses of 10 µl of each PCR reaction mixture in a 1.5% agarose gel, and bands were visualized by ethidium bromide staining. Experiments were repeated >=  triplicate.

The primers chosen for sense (3'-5') and antisense (5'-3'), respectively, were: for human Tie2 (GenBankTM accession number L06139) ATCCCATTTGCAAAGCTTCTGGCTGGC and TGTGAAGCGTCTCACAGGTCCAGGATG (512 base pairs of PCR product); for human Ang1 (GenBankTM accession number U83508) GGGGGAGGYYGGACTGTAAT and AGGGCACATTTGCACATACA (362 base pairs); for human Ang2 (GenBankTM accession number AF004227) GGATCTGGGGAGAGAGGAAC and CTCTGCACCGAGTCATCGTA (535 base pairs); and for human GAPDH (GenBankTM accession number X01677) TGAAGGTCGGAGTCAACGGATTTG and CATGTGGGCCATGAGGTCCACCAC (983 base pairs). The number of cycles was 40 for Tie2, Ang1, and Ang2 and 28 for glyceraldehyde-3-phosphate dehydrogenase.

RT-PCR was performed in each case using exactly the same amount of RNA. PCR was always performed in parallel for each primer pair and the PCR products were separated on the same gel. The linear range of amplification was tested for all primer pairs by performing PCR with an increasing number of cycles. PCR for glyceraldehyde-3-phosphate dehydrogenase was performed as an internal control, demonstrating comparable starting amounts of cDNA for all extracts.

Northern Blots of Human ECs-- Expression in human ECs of the angiopoietins, VEGF, Tie1, and Tie2 was examined on RNA blots. RNAs were isolated from low passage- number HUVECs, aorta (human aortic ECs), dermal microvasculature (all purchased from Clonetics, San Diego, CA), and cutaneous fat pad microvasculature (a gift from Dr. J. Springhorn, Alexion Pharmaceuticals) endothelial cells. The cells were grown on tissue culture plastic using recommended basal medium, 5% FBS, and supplements (Clonetics) at 37 °C in a humidified 5% CO2 atmosphere. To harvest RNAs, media was removed from confluent cultures, and the cell monolayer was briefly rinsed with phosphate-buffered saline then lysed with guanidinium thiocyanate and processed as described (37). Total RNAs were resolved by electrophoresis on replicate formaldehyde-agarose gels, blotted to nylon membranes, and hybridized with radiolabeled cDNA probes. As a control, the blots also included poly(A) + RNAs from human placenta and lung (from CLONTECH). The Ang1, Ang2, Tie1, and Tie2 probes were radiolabeled inserts from human cDNAs; the VEGF probe was the entire insert of a mouse VEGF164 cDNA.2

BIAcore and Western Blot Detection of Ang2 Protein in HUVEC-conditioned Media-- HUVEC expression of Ang2 RNAs led us to ask whether these cells secrete Ang2 protein into the culture medium. Conditioned media (CM) was collected from HUVEC cultures as follows. The medium from established HUVEC cultures was replaced with serum-free defined medium and grown for 24 h, whereupon the cells were refed with fresh-defined medium. After an additional 24 h of cell growth, this HUVEC-CM was harvested, concentrated 10-fold by filtration (Amicon, 10,000 MWCO), and then assayed for the presence of Tie2 binding activities on a Tie2-Fc-coupled BIAcore sensor chip (Amersham), as described previously (27). HUVEC-CM contained 190 resonance units of Tie2-specific binding activity or roughly a 10-fold greater signal than that seen with CM from angiopoietin-negative cell media (data not shown).

To distinguish whether this Tie2 binding activity was Ang2 protein, the HUVEC-CM was further concentrated to 50× (Centricon, 3000 MWCO), fractionated on nonreducing SDS-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membranes, and then analyzed by immunodetection with antisera specific to Ang1 and Ang2.

Statistical Analysis-- Results were expressed as mean ±S.E. of the mean. Statistical significance was evaluated using unpaired Student's t test for comparisons between two means and ANOVA followed by Scheffe's procedure for more than two means. A value of p < 0.05 was interpreted as statistically significant.

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Effects of Angiopoietin-1 and -2 on Endothelial Cell Proliferation, DNA Synthesis, and Apoptosis-- To evaluate cellular proliferation in response to Ang1* or Ang2, we stimulated HUVECs with increasing amounts of Ang1*, Ang2, or VEGF, a known EC-specific mitogen, for 48 h and performed MTS analysis. This assay was previously shown to accurately reflect cell number (35). VEGF treatment led to a significant dose-dependent increase in optical density, positively correlating with an increase in absolute cell number; a half-maximal response was between 1 and 10 ng/ml. In contrast, neither stimulation with Ang1* nor Ang2 over a wide dose range led to a significant increase in cell number (data not shown). In addition, the influence of Ang1* and -2 on DNA synthesis in HUVECs was evaluated by [3H]thymidine incorporation (data not shown). Phorbol 12-myristate 13-acetate (20 ng/ml) was used as a positive control and led to a 5.2 ± 0.2-fold increase in DNA synthesis compared with control. Whereas 10 ng/ml VEGF induced a 2.1 ± 0.03-fold significant increase in [3H]thymidine incorporation (p < 0.05), neither Ang1*, Ang2, nor a combination of both led to any change in DNA synthesis over base line. Moreover, combining VEGF with Ang1* (2.2 ± 0.1-fold) or Ang2 (2.1 ± 0.01) did not alter the effect of VEGF alone on DNA synthesis. Similar results were obtained using lower concentrations of Ang1* and Ang2 alone or for any combination tested (not shown).

The effect of 48-h stimulation with Ang1* and Ang2 on cell cycle progression and apoptosis induced by serum withdrawal (2% FBS) were investigated in HUVECs. Whereas VEGF stimulation increased the proportion of cells in S-phase (17.8 ± 3.0 versus 6.8 ± 2.2%; p < 0.05), results obtained for Ang1* and Ang2 stimulation did not exceed base-line values (Table I). Similarly, 10 ng/ml VEGF significantly reduced the amount of apoptotic cells in low serum condition (18.9 ± 3.5 versus 33.7 ± 6.7% for control, p < 0.05), whereas neither Ang1* nor Ang2 exerted any pro- or anti-apoptotic effects under the conditions tested.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Effect of angiopoietin-1 and -2 on HUVEC cell cycle and apoptosis induced by serum withdrawal
HUVECs were stimulated with Ang1*, Ang2 (1 µg/ml each), VEGF (10 ng/ml), or control (no factor added) in serum-reduced medium (2% FBS) for 48 h. Cell cycle analysis using flow cytometry was performed after ethanol fixation and propidium iodide staining. For quantification of apoptosis, floating and adhesive cells were collected and analyzed.

Angiopoietin-1, but Not Angiopoietin-2, Is Chemotactic for Endothelial Cells-- Using a modified 48-well chemotaxis Boyden chamber, we assessed the chemotactic response of HUVECs to increasing amounts of Ang1* and Ang2 and compared it to that of VEGF, which is known to be chemotactic for ECs (40). Ang1* led to a significant, dose-dependent increase in directed migration of HUVECs, with a half-maximal effect at a dose of 10 ng/ml (Fig. 1). Whereas at concentrations of 1 and 10 ng/ml the chemotactic effect of Ang1* seemed to be somewhat less than that of VEGF, the response at higher doses (100 and 1000 ng/ml) was indistinguishable. In contrast, Ang2 over a wide dose range did not exert any chemotactic properties.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 1.   Chemotactic response of HUVECs to increasing concentrations of VEGF, Ang1*, or Ang2 as indicated. Diluted test substances were placed in the lower chamber of a 48-well microchemotaxis Boyden apparatus. A total 2.5 × 105 cells/well were seeded into the upper chambers, and cells were allowed to migrate for 5 h through 8-µm pores of a fibronectin/gelatin-coated polycarbonate membrane placed between upper and lower chambers. After the migration period, nonmigrating cells were removed from the upper side of the membrane, the membrane was stained using a Giemsa solution, and migrated cells were quantified by counting nuclei in three random high power fields (HPF, 100×)/well. Data points represent migrated cell numbers/quadruplicate wells ±S.E. *p < 0.05 versus control (medium with vehicle solution, no factors added).

To establish specificity of the observed effect on directed cell migration, we applied Ang1* at two different doses (0.1 and 1 µg/ml) with or without a 10-fold excess to reach maximal saturating concentration of either soluble Tie2 receptor (rTie2-Fc) or soluble Tie1 receptor (rTie1-Fc) (1 and 10 µg/ml) to the lower chambers of the Boyden apparatus. As shown in (Fig. 2), rTie2-Fc, competing off Ang1* from its cellular receptor due to its molar excess, completely blocked the chemotactic effect of Ang1* on HUVECs. In contrast, rTie1-Fc, a closely related orphan receptor that does not bind Ang1, was not sufficient to inhibit the migratory response. Both results taken together indicate that the observed effects are due to Ang1 in the solution and cannot be explained by remaining impurities after the purification process of Ang1/2.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 2.   Migration assay demonstrating that the chemotactic effect of HUVECs toward Ang1* is blocked by excess soluble Tie2 receptor (rTie2-Fc) but not by soluble Tie1 receptor (rTie1-Fc). The experiment was performed as described in Fig. 1 by applying two different concentrations of Ang1 (0.1 and 1 µg/ml) to the lower migration chambers with or without co-incubation with a 10-fold excess (1 and 10 µg/ml) of either rTie1-Fc or rTie2-Fc. Bars represent mean ±S.E. from quadruplicate wells. HPF, high power field (100×). *p < 0.05 versus control (medium plus vehicle buffer).

To distinguish between chemotactic and chemokinetic effects of Ang1 on ECs, we performed a modified checkerboard analysis in which the concentration of chemoattractant above and below the filter was varied. Table II indicates that significant migration was observed only when a concentration gradient of Ang1* between upper and lower compartments was established, a finding typical of factors inducing chemotaxis. In contrast, adding equivalent concentrations of Ang1* to both sides of the filter did not enhance cell movement, thereby excluding a significant chemokinetic effect of Ang1.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Checkerboard analysis of HUVECs in response to angiopoietin-1 using modified Boyden chamber
Varied concentrations of Ang1* (in µg/ml) were placed in the upper (containing cells) and/or lower (stimulus) chamber as indicated. Cells were allowed to migrate for 5 h at 37 °C. Migration was quantified by counting the number of cells migrated to the lower side of a polycarbonate membrane containing 8-µm pores. Cells co-incubated with indicated factors were preincubated for 10 min at 37 °C before being added to the assay. Numbers represent mean ± S.E. of three high power fields (100×) from four wells. Note that to induce a chemotactic response, an increasing concentration gradient of Ang1* between upper and lower chambers is required.

To establish specificity, the chemotactic response of ECs and SMCs from different tissue origins toward Ang1* and Ang2 were determined. Again, Ang2 did not exert any effect on either cell type. Ang1*, however, stimulated directed migration in bovine aortic and HM ECs, whereas no effect on rat or human vascular SMCs was observed (Fig. 3). These results indicate that the chemotactic effect of Ang1 is cell-type specific but not limited to ECs of a certain origin.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 3.   Cell-type-specific chemotactic effects of Ang1* and Ang2. Migration assays were performed as described in Fig. 1 utilizing human microvascular cells (HMECs), bovine aortic endothelial cells (BAECs), and rat and human vascular smooth muscle cells (VSMCs). Ang1* or Ang2 at 0.2 µg/ml was added to the lower chambers of the Boyden apparatus. Bars represent the mean ±S.E. from quadruplicate wells. HPF, high power field (100×). *p < 0.05 versus control. n.s., not significant.

Angiopoietin-2 Inhibits the Chemotactic Effect of Angiopoietin-1-- Because previous findings have indicated that is a naturally occurring antagonist for Tie2, we investigated if Ang2 is able to suppress the chemotactic response evoked by Ang1 in HUVECs. When increasing amounts of Ang2 were added to a constant amount of Ang1 (100 ng/ml) in the lower chamber of a Boyden chamber, the chemotactic effect of Ang1 on these cells was gradually inhibited (Fig. 4). To completely suppress the number of migrated cells to control value, an 8-10-fold excess of Ang2 over Ang1 was required. This result indicates that Ang2 is able to compete with Ang1 for Tie2 receptor binding sites, but binding of Ang2 to Tie2 does not lead to the same receptor signal transduction events necessary to stimulate chemotaxis.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 4.   Inhibition of Ang1*-induced chemotaxis by Ang2. Migration assay was performed as described in Fig. 1, utilizing HUVECs. Either control (medium supplemented with vehicle buffer solution) or Ang1* at 100 ng/ml in combination with increasing amounts of Ang2 (0-1000 ng/ml) were applied to lower chambers of the Boyden apparatus, and migration was quantified after 5 h of incubation. At 800 and 1000 ng/ml Ang2 combined with 100 ng/ml Ang1*, corresponding to an 8- and 10-fold excess of Ang2 over Ang1*, there was no statistical difference compared with control values (no Ang1*). Data points represent the mean ±S.E. from quadruplicate wells. HPF, high power field (100×). *p < 0.05 versus control.

Fibroblasts Stably Expressing Transfected Tie2 Receptor Exert Chemotactic Responses toward both Angiopoietin-1 and -2-- To determine the chemotactic effects of Ang1 and Ang2 on nonendothelial cells ectopically expressing Tie2 receptors, migration assays using NIH 3T3 fibroblasts stably transfected with Tie2 receptor were performed and compared with mock-transfected fibroblasts. (PDGF-BB, a known strong chemotactic substance for fibroblasts and SMCs (41), served as a positive control (10 ng/ml)). The transfected receptors were genetically engineered to minimize basal receptor phosphorylation in order to decrease background activation (29). In mock NIH 3T3 cells, neither Ang1* nor Ang2 induced any significant increase in cell migration (Fig. 5A, left bars). In contrast, NIH 3T3 fibroblasts stably expressing transfected Tie2 receptors demonstrated a marked increase in cell migration to 466 ± 6% for 100 ng/ml Ang1* and to 410 ± 13% for the same amount of Ang2 compared with control buffer solution (p < 0.05 each (Fig. 5A, middle bars)). A 10-fold excess of rTie2-Fc applied to the lower compartment of the Boyden apparatus completely abolished the chemotactic effect of both Ang1* and Ang2 on 3T3-Tie2 fibroblasts (147 ± 16% for Ang1*, 120 ± 21% for Ang2, p = not significant versus control), whereas chemotaxis toward PDGF-BB was not influenced by excess rTie2-Fc (Fig. 5A, right bars). Thus, fibroblasts ectopically expressing Tie2 receptor demonstrated a specific chemotactic response to both Ang1* and Ang2; in contrast, ECs exhibited a specific chemotactic response only to Ang1*.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 5.   A, migration assays using NIH 3T3 fibroblasts (mock-transfected control) and 3T3 fibroblasts ectopically expressing Tie2 receptor derived from stable transfections (3T3/Tie2). Medium containing vehicle buffer solution (control), Ang1* or Ang2 (200 ng/ml), or PDGF-BB (10 ng/ml) as positive control were administered into the lower chambers of the Boyden apparatus. In the case of the right bar group, soluble Tie2 receptor (rTie2-Fc) was added in 10-fold excess (2 µg/ml). B, migration assay using NIH 3T3 fibroblasts (mock-transfected control) and MG87 fibroblasts (3T3-derived cell line) into which a chimeric receptor consisting of the ectodomain of TrkC fused to the cytoplasmic domain of Tie2 was stably transfected (MG87/TrkC-Tie2). Medium containing vehicle buffer solution (control), NT-3 at 10 ng/ml, or PDGF at 10 ng/ml (positive control) were applied to the lower chambers of the Boyden apparatus. Assays were performed as described in Fig. 1. Bars represent the mean ±S.E. of migrated cells/high power field (HPF, 100×) from quadruplicate wells. *p < 0.05 versus control.

Moreover, we investigated other potential ways in which activation of the Tie2 catalytic domain could produce chemotactic responses. MG87 fibroblasts (a 3T3 variant cell line) were stably transfected with a chimeric receptor consisting of the ectodomain of TrkC fused to the cytoplasmic domain of Tie2 (MG87/TrkC-Tie2 fibroblasts) (42). Evidence that the chimeric receptor is functional had been previously shown by tyrosine phosphorylation of the TrkC-Tie2 chimera upon addition of NT-3 to these cells (27). We employed these cells for migration assays and compared the responses to those of 3T3 mock-transfected cells. Since both 3T3 as well as MG87 fibroblasts possess endogenous PDGF receptors, PDGF-BB was used as a positive control, yielding a strong chemotactic response in both cell types (Fig. 5B) compared with control medium. In 3T3 cells lacking the TrkC receptor, the addition of NT-3 at 10 ng/ml did not result in any chemotactic effect (142 ± 10% migrated cells versus control, p = not significant). In contrast, MG87/TrkC-Tie2 cells showed a pronounced chemotactic response to 10 ng/ml NT-3 (increase to 399 ± 4% versus control, p < 0.05), indicating that activation of this chimeric receptor, leading to autophosphorylation of the cytoplasmic Tie2-domain, is sufficient to initiate a signal cascade resulting in enhanced cellular motility.

Angiopoietin-1, -2, and Tie2 Receptor mRNA Expression in Human Vascular Specimens and Cultured Cells Analyzed by RT-PCR-- Ang1, Ang2, and Tie2 mRNA expression was investigated using RT-PCR in explanted human specimens of internal mammary artery, radial artery, and saphenous vein. As shown in (Fig. 6), both Ang1 as well as Ang2 mRNA were detectable in all three tissues. Furthermore, Tie2 mRNA expression was documented in all specimens investigated. Nontransfected NIH 3T3 fibroblasts did not express Ang1/2 or Tie2 and served as negative controls (Fig. 6, lane 4), whereas amplification of glyceraldehyde-3-phosphate dehydrogenase was used as control for comparable amount and quality of mRNA among samples. Positive controls included PCR amplification of cloning vectors containing full-length cDNAs for Ang1, Ang2, and Tie2, yielding PCR products in agreement with the predicted sizes (not shown). Successful expression of Tie2 receptor mRNA in the stably transfected 3T3 fibroblasts was also confirmed by RT-PCR (Fig. 6, lane 5). As expected, Tie2 mRNA was easily detectable in different ECs (HUVECs, human microvascular endothelial cells, BAECs; in Fig. 6, lane 6 only shown for HUVECs). Ang1 as well as Ang2 mRNA were observed not only in human vascular SMCs but in ECs as well (lanes 6 and 7).


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 6.   RT-PCR demonstrating expression of Ang1, Ang2, and Tie2 receptor mRNA in explanted segments of normal human internal mammary artery (lane 1), radial artery (lane 2), and saphenous vein (lane 3). Lane 4, mock-transfected NIH-3T3 fibroblasts; lane 5, stably transfected 3T3 fibroblasts expressing Tie2-receptor, used for migration experiments; lane 6, HUVECs; lane 7, human vascular SMCs. Amplification of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) demonstrates comparable RNA amount and quality among samples. Sizes of predicted PCR products are indicated by arrows. L, DNA-ladder; bp, base pairs.

Angiopoietin-1, -2, and Tie2 Receptor mRNA Expression in Cultured Endothelial Cells Analyzed by Northern Blot-- When Northern blot analysis was performed on cultured ECs, expression of Ang2 as well as Tie1 and Tie2 was confirmed at the mRNA level in HUVECs, cultured human aortic ECs, and cultured human microvascular ECs (Fig. 7). In contrast, human cutaneous fat pad ECs expressed an extraordinary amount of Ang1 transcripts but were negative for Ang2.


View larger version (73K):
[in this window]
[in a new window]
 
Fig. 7.   Expression of Ang1, Ang2, Tie1, Tie2, and VEGF mRNAs in human ECs. Total RNAs (10 µg) from various cultured human ECs and poly(A) + RNAs (2 µg) from human placenta and lung were fractionated on replicate formaldehyde-agarose gels, transferred to nylon membranes, and hybridized with radiolabeled cDNA probes as indicated. HAEC, human aortic ECs; HMVEC, dermal microvascular ECs; HUCEC, human cutaneous fat pad ECs.

Angiopoietin-2, but Not angiopoietin-1, Protein Is Present in HUVEC-conditioned Media-- Analysis of conditioned media from cultured HUVECs by Western blot analysis disclosed detectable Ang2 but no Ang1 (Fig. 8). Ang2 was observed to exist in oligomeric forms that closely mimic those present in purified, bioactive Ang2.3


View larger version (64K):
[in this window]
[in a new window]
 
Fig. 8.   Secreted Ang2 protein in HUVEC-CM. HUVEC-CM was harvested (see text), resolved on nonreducing SDS-polyacrylamide gels, and analyzed by Western blot with antisera specific for Ang1 and Ang2, as indicated. Ang2 but not Ang1 protein is clearly detected.

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Recent gene targeting experiments disrupting either Tie2 (22, 24) or Ang1 (28) have clearly established a significant role for the Tie2/Ang1 system in embryonic angiogenesis. Whereas ECs are absent from VEGF-R2 null mice (8), ECs in Tie2 null mice are present in normal numbers and are assembled into tubes; the vessels of Tie2 mice, however, appear immature, lacking the extent of branching and organization typical for normal vessels. Similar vascular defects, although less severe, are seen in Ang1 null mice (28): ECs are aberrantly rounded, do not spread and/or flatten normally, are loosely associated with the underlying matrix, and do not properly associate with periendothelial cells. These findings were interpreted as evidence that the physiologic roles of the Tie2/Ang system in angiogenesis come into play subsequent to regulation by VEGF, although the exact nature of Tie2/Ang remained to be clarified. Our finding of a strong and specific chemotactic effect of Ang1 on ECs is to our knowledge the first description of a direct biological function of the Tie2/Ang1-system, implies a close spatial and polarized interaction between Ang1-secreting cells and ECs expressing the Tie2 receptor, and thus establishes putative basis for defective angiogenesis in mice lacking Tie2 or Ang1.

The critical contribution of EC migration, as opposed to proliferation, in angiogenesis was previously demonstrated in a classic experiment performed in the rat cornea by Sholley et al. (43). Vascular sprouting could be induced and continued for more than 2 days, despite irradiation treatment sufficient to suppress DNA synthesis. Initiation of angiogenesis in this model was thus interpreted to reflect the dominant impact of EC migration.

Tie2 receptor and Ang1 mRNA were easily detectable in normal human arterial and venous specimens. Tie2 expression was recently shown by immunohistochemical staining to be present in quiescent adult tissues, including vascular endothelium, (15); the extent of Tie2 phosphorylation was interpreted as inferential evidence for the presence of Tie2 ligand(s) in quiescent adult tissues, consistent with previous findings that Ang1 is widely expressed in adult tissues (29). Our direct demonstration of Ang1 in the adult vessel wall is in agreement with this notion.

Tie2/Ang1 expression pattern, together with the novel finding of an EC-specific chemoattractive effect of Ang1, suggests two possible functions of the Tie2/Ang1-system. First, in normal adult quiescent vessels, periendothelial cells (pericytes, SMCs) constitutively secrete Ang1, enhancing contact between neighboring ECs and between ECs/periendothelial cells, thus maintaining endothelial integrity and orientation of ECs on the basal lamina. Disruption of the endothelial monolayer could lead to up-regulation of Ang1 expression in surrounding cells and/or changes in Tie2 receptor expression in ECs, which have lost contact with adjacent ECs. Up-regulation of VEGF expression, resulting in a strong mitogenic effect on ECs and subsequent reendothelialization of denuded areas, was recently demonstrated in response to balloon injury (15). The chemotactic effect of Ang1 may be involved as an adjunct to VEGF in recruiting ECs to initiate and accelerate reendothelialization. In the Ang1 and Tie2 knockout mice, the absent impact of Ang1 on ECs may contribute to the poor association between ECs and periendothelial cells as well as the lack of EC spreading, resulting in immature appearing vessels.

Second, under conditions of postnatal angiogenesis, such as tissue ischemia or tumor growth, the chemoattractive effect of Ang1 on ECs may be important for initiation of new capillary sprouting, as well as movement of ECs toward each other required for fusion into capillary structures. Such three-dimensional EC fusion processes may be responsible for the corkscrew-like appearance typical of collaterals in ischemic areas or neovascularized tumors. In this regard, the effects of Ang1 may be achieved in a tightly localized fashion, possibly requiring a concentration gradient of Ang1 to induce an effect. In vitro systems such as the tube formation assay may fail to disclose an effect of Ang1 because exogenous factors are introduced "on top" of the cells, disregarding concentration gradients of molecules that may be more typical of angiogenesis in vivo. The trigger for increased responsiveness of the Tie2/Ang system remains enigmatic; unlike VEGF, which is known to be positively regulated by hypoxia (44), Ang1 seems not to be up-regulated by hypoxia (45). Enhanced expression of Tie2, however, has been observed in the vascular endothelium of metastatic melanomas (46) and during ovulation and wound healing (47), suggesting the possibility that Tie2/Ang1 is regulated at the level of receptor expression.

A second ligand for the Tie2 receptor, named Ang2, having nearly 60% homology in amino acid sequence with Ang1, was recently identified (29). Two experimental findings were interpreted as evidence to suggest that Ang2 might represent a naturally occurring antagonist for Tie2. First, Ang2 was shown to bind to Tie2 expressed on ECs without transducing the receptor and was capable as well of blocking Ang1-induced receptor phosphorylation (29). Second, transgenic overexpression of Ang2 led to disruption of blood vessel formation in the mouse embryo (29). Our in vitro finding that Ang1 chemotactic activity for ECs can be blocked by adding increasing amounts of Ang2 is consistent with these results and suggests a negative regulatory function of Ang2 versus Ang1 by competitive binding to Tie2 without subsequent autophosphorylation of the cytoplasmic tyrosine kinase domain. Moreover, our demonstration of Ang2 expression in the normal quiescent vessel wall has not been previously reported and suggests a delicate balance of vessel maintenance by positive and negative regulators.

The lack of available antibodies for immunostaining precluded identification of cell type-specific Ang2 expression in intact vascular specimens. Studies of cultured cells, however, disclosed that Ang2 expression was not limited to SMCs but could be detected in ECs as well. Specifically, Ang2 mRNA was identified by RT-PCR in HUVECs, by Northern analysis in HUVECs, human aortic endothelial cells, and dermal microvasculatures endothelial cells, and by Western analysis in HUVECs. In contrast, although Ang1 was identified by RT-PCR in HUVECs, it was not detected by Northern analysis of HUVECs, human aortic endothelial cells, or human microvascular endothelial cells nor Western analysis of conditioned media of HUVECs. These findings appear to corroborate the results of in situ hybridization demonstrating endothelial expression of Ang2 transcripts in vivo (29). An apparent exception are cutaneous fat pad microvasculatures endothelial cells, which by Northern analysis were shown to express an extraordinary amount of Ang1 transcripts but were negative for Ang2. It is unclear what this finding means since detection of Ang1 expression in vivo has generally been shown to localize to nonendothelial cells in vivo (27). For those ECs that are able to express Ang2, it is intriguing to propose an autocrine mode of Ang2 expression whereby ECs might block themselves from the influence of externally derived Tie2 ligand(s).

Previous reports (29) have indicated that although Ang2 antagonizes Ang1-induced receptor phosphorylation in ECs, it is surprisingly equivalent to Ang1 for promoting Tie2 phosphorylation when the receptor is ectopically expressed in fibroblasts. Our demonstration of a similar chemotactic response of Tie2-expressing fibroblasts for Ang1 and Ang2 extends these previous findings to a functional level. Thus fibroblasts appear to express a sufficient "repertoire" of intracellular adaptor proteins to effectively interact with ectopically expressed Tie2 receptor and trigger a signal cascade, resulting in cell migration. This is confirmed in particular by our finding that fibroblasts transfected with a chimeric receptor encoding the cytoplasmic domain of Tie2 fused to TrkC extracellular binding domain, a neuron-specific receptor for NT-3, can be stimulated to migrate by adding NT-3. The differential effect of Ang2 in endothelial cells and nonendothelial cells may be due to a lack of critical signaling element(s) in the former. An alternative explanation is likely required, however, given that chemotaxis is the end result of Tie2 receptor activation in both cell types. One potential explanation for this paradigm is that binding of Tie2 by Ang2 leads to preferred heterodimerization of the receptor with another membrane component such as Tie1 or an as yet unidentified EC-specific receptor, "trapping" Tie2 monomers and thereby preventing reciprocal phosphorylation of cytoplasmic receptor kinase domains. Further experiments, including concomitant transfection of fibroblasts with Tie2 and Tie1, will be required to substantiate this concept.

    ACKNOWLEDGEMENTS

The authors are grateful to Drs. Samuel Davis, Terence Ryan, Thomas Daly, and Nick Papadopoulos of the Protein Sciences Division of Regeneron for recombinant Ang1*, Tie1-Fc, and Tie2-Fc and to Tammy Huang for technical assistance.

    FOOTNOTES

* The work was supported in part by National Institutes of Health Grants HL 40518, HL 53354, HL 57516 and Academic Award in Vascular Medicine HL 02824 (from NHLBI).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed: St. Elizabeth's Medical Center of Boston, 736 Cambridge St., Boston, MA 02135. Tel.: 617-789-2392; 617-779-6362.

1 VEGF, vascular endothelial growth factor; EC, endothelial cell; FBS, fetal bovine serum; HUVEC, human umbilical vein endothelial cell; NT-3, neurotrophin 3; PDGF, platelet-derived growth factor; EGF, epidermal growth factor; SMC, smooth muscle cells; Ang, angiopoietin; HM, human microvascular; MTS, 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium; RT, reverse transcription; PCR, polymerase chain reaction; CM, conditioned media; rTie1-Fc, Tie1 receptor-Fc.

2 P. Maisonpierre, unpublished data.

3 S. Davis, unpublished data.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

  1. Ullrich, A., and Schlessinger, J. (1990) Cell 61, 203-212[Medline] [Order article via Infotrieve]
  2. Schlessinger, J., and Ullrich, A. (1992) Neuron 9, 383-391[Medline] [Order article via Infotrieve]
  3. Marschall, C. J. (1995) Cell 80, 179-185[Medline] [Order article via Infotrieve]
  4. Risau, W. (1995) FASEB J. 9, 926-933[Abstract/Free Full Text]
  5. Mustonen, T., and Alitalo, K. (1995) J. Cell Biol. 129, 895-898[Medline] [Order article via Infotrieve]
  6. Joukov, V., Pajusola, K., Kaipainen, A., Chilov, D., Lahtinen, I., Kukk, E., Saksela, O., Kalkkinen, N., and Alitalo, K. (1996) EMBO J. 15, 290-298[Abstract]
  7. Fong, G-H., Rossant, J., Gerstenstein, M., and Breitman, M. L. (1995) Nature 376, 66-70[CrossRef][Medline] [Order article via Infotrieve]
  8. Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X-F., Breitman, M. L., and Schuh, A. C. (1995) Nature 376, 62-66[CrossRef][Medline] [Order article via Infotrieve]
  9. Couffinhal, T., Kearney, M., Witzenbichler, B., Chen, D., Murohara, T., Losordo, D. W., Symes, J. F., and Isner, J. M. (1997) Am. J. Pathol. 150, 1673-1685[Abstract]
  10. Plate, K. H., Breier, G., Weich, H. A., and Risau, W. (1992) Nature 359, 845-848[CrossRef][Medline] [Order article via Infotrieve]
  11. Plate, K. H., Breier, G., Millauer, B., Ullrich, A., and Risau, W. (1993) Cancer Res. 53, 5822-5827[Abstract]
  12. Folkman, J. (1995) Nat. Med. 1, 27-30[Medline] [Order article via Infotrieve]
  13. Isner, J. M., Pieczek, A., Schainfeld, R., Blair, R., Haley, L., Asahara, T., Rosenfield, K., Razvi, S., Walsh, K., and Symes, J. (1996) Lancet 348, 370-374[CrossRef][Medline] [Order article via Infotrieve]
  14. Takeshita, S., Zheng, L. P., Brogi, E., Kearney, M., Pu, L. Q., Bunting, S., Ferrara, N., Symes, J. F., and Isner, J. M. (1994) J. Clin. Invest. 93, 662-670[Medline] [Order article via Infotrieve]
  15. Tsurumi, Y., Murohara, T., Krasinski, K., Dongfen, C., Witzenbichler, B., Kearney, M., Couffinhal, T., and Isner, J. M. (1997) Nat. Med. 3, 879-886[Medline] [Order article via Infotrieve]
  16. Dumont, D. J., Fong, G-H., Fong, M. C., Puri, G., Gradwohl, G., Alitalo, K., and Breitman, M. L. (1995) Dev. Dyn. 203, 80-92[Medline] [Order article via Infotrieve]
  17. Maisonpierre, P. C., Goldfarb, M., Yancopoulos, G. D., and Gao, G. (1993) Oncogene 8, 1631-1637[Medline] [Order article via Infotrieve]
  18. Sato, T. N., Qin, Y., Kozak, C. A., and Audus, K. L. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 9355-9358[Abstract]
  19. Ziegler, S. F., Bird, T. A., Schneringer, K. A., Schooley, K. A., and Baum, P. R. (1997) Oncogene 8, 663-670
  20. Dumont, D. J., Yamaguchi, T. P., Conlon, R. A., Rossant, J., and Breitman, M. L. (1992) Oncogene 7, 1471-1480[Medline] [Order article via Infotrieve]
  21. Schnurch, H., and Risau, W. (1993) Development 119, 957-968[Abstract/Free Full Text]
  22. Sato, T. N., Tozawa, Y., Deutsch, U., Wolburg-Buchholz, K., Fujiwara, Y., Gentron-Maguire, M., Gridley, T., Wolburg, H., Risau, W., and Qin, Y. (1995) Nature 376, 70-74[CrossRef][Medline] [Order article via Infotrieve]
  23. Puri, M. C., Rossant, J., Alitalo, K., Bernstein, A., and Partanen, J. (1995) EMBO J. 14, 5884-5891[Abstract]
  24. Dumont, D. J., Gradwohl, G., Guo-Hua, F., Puri, M. C., Gertsenstein, M., Auerbach, A., and Breitman, M. L. (1994) Genes Dev. 8, 1897-1909[Abstract]
  25. Vikkula, M., Boon, L. M., Carraway, K. L., III, Calvert, J. T., Diamonti, A. J., Goumnerov, B., Pasyk, K. A., Marchuk, D. A., Warman, M. L., Cantley, L. C., Mulliken, J. B., and Olsen, B. R. (1996) Cell 87, 1181-1190[Medline] [Order article via Infotrieve]
  26. Olofsson, B., Pajusola, K., Kaipainen, A., vonEuler, G., Joukov, V., Saksela, O., Orpana, A., Pettersson, R. F., Alitalo, K., and Eriksson, U. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 2576-2581[Abstract/Free Full Text]
  27. Davis, S., Aldrich, T. H., Jones, P. F., Acheson, A., Compton, D. L., Jain, V., Ryan, T. E., Bruno, J., Radziejewski, C., Maisonpierre, P. C., and Yancopoulos, G. D. (1996) Cell 87, 1161-1169[Medline] [Order article via Infotrieve]
  28. Suri, C., Jones, P. F., Patan, S., Bartunkova, S., Maisonpierre, P. C., Davis, S., Sato, T., and Yancopoulos, G. D. (1996) Cell 87, 1171-1180[Medline] [Order article via Infotrieve]
  29. Maisonpierre, P., Suri, C., Jones, P., Bartunkova, S., Wiegand, S., Radziejewski, C., Compton, D., McClain, J., Aldrich, T., Papadopoulos, N., Daly, T., Davis, S., Sato, T., and Yancopoulos, G. (1997) Science 277, 55-60[Abstract/Free Full Text]
  30. Haimovitz-Friedman, A., Balaban, N., McLoughlin, M., Ehleiter, D., Michaeli, J., Vlodavsky, I., and Fuks, Z. (1994) Cancer Res. 115, 245-247
  31. Spyridopoulos, I., Brogi, E., Kearney, M., Sullivan, A. B., Cetrulo, C., Isner, J. M., and Losordo, D. W. (1997) J. Mol. Cell. Cardiol. 29, 1321-1330[CrossRef][Medline] [Order article via Infotrieve]
  32. Jaffe, E. A., Nachman, R. L., Becker, C. G., and Minick, C. R. (1973) J. Clin. Invest. 52, 2745-2756[Medline] [Order article via Infotrieve]
  33. Mader, S. L. (1992) J. Gerontol. Biol. Sci. 47, B32-B36
  34. Pickering, J. G., Weir, L., Rosenfield, K., Stetz, J., Jekanowski, J., and Isner, J. M. (1992) J. Am. Coll. Cardiol. 20, 1430-1439[Medline] [Order article via Infotrieve]
  35. Buttke, T. M., McCubrey, J. A., and Owen, T. C. (1993) J. Immunol. Methods 30, 233-240
  36. Falk, W., Goodwin, R. H., and Leonard, E. J. (1980) J. Immunol. Methods 33, 239-247[CrossRef][Medline] [Order article via Infotrieve]
  37. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159[CrossRef][Medline] [Order article via Infotrieve]
  38. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed., pp. 204-210, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
  39. Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi, R., Horn, G. T., Mullis, K. G., and Ehrlich, H. A. (1988) Science 239, 487-491[Medline] [Order article via Infotrieve]
  40. Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Kendraprasad, H., Eberhardt, C., Declercq, C., Pawling, J., Moons, L., Collen, D., Risau, W., and Nagy, A. (1996) Nature 380, 435-439[CrossRef][Medline] [Order article via Infotrieve]
  41. Grotendorst, C., Chang, T., Seppa, H. E. J., Kleinman, H. K., and Martin, G. R. (1982) J. Cell. Physiol. 113, 261-266[Medline] [Order article via Infotrieve]
  42. Glass, D. J., Nye, S. H., Hantzopoulos, P., Macchi, M. J., Squinto, S. P., Goldfarb, M., and Yancopoulos, G. D. (1991) Cell 66, 405-413[Medline] [Order article via Infotrieve]
  43. Sholley, M. M., Ferguson, G. P., Seibel, H. R., Montour, J. L., and Wilson, J. D. (1984) Lab. Invest. 51, 624-634[Medline] [Order article via Infotrieve]
  44. Levy, A. P., Levy, N. S., Wegner, S., and Goldberg, M. A. (1995) J. Biol. Chem. 270, 13333-13340[Abstract/Free Full Text]
  45. Enholm, B., Paavonen, K., Ristimaki, A., Kumar, V., Gunji, Y., Klefstrom, J., Kivinen, L., Laiho, M., Olofsson, B., Joukov, V., Eriksson, U., and Alitalo, K. (1997) Oncogene 14, 2475-2483[CrossRef][Medline] [Order article via Infotrieve]
  46. Kaipainen, A., Vlaykova, T., Hatva, E., Bohling, T., Jekunen, A., Pyrhonen, S., and Alitalo, K. (1994) Cancer Res. 54, 6571-6577[Abstract]
  47. Korhonen, J., Partanen, J., Armstrong, E., Vaahtokari, A., Elenius, K., Jalkanen, M., and Alitalo, K. (1992) Blood 80, 2548-2555[Abstract]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.